Teva Pharmaceutical Industries received a boost as UBS reaffirmed its "Buy" rating and raised the price target to $48, up from $36.62. This follows positive Phase 2a clinical trial results for TEV '408, a drug showing significant prevention of intestinal damage in celiac disease patients with good safety. The company’s low implied volatility also signals potential stock gains based on historical trends. These developments highlight Teva's promising growth and new treatment prospects beyond current gluten-free diets.
A newly created wallet withdrew 600,007 Uniswap (UNI) tokens from Binance, valued at about $4.61 million at the time of transfer. This large, single withdrawal from Binance to a new address is notable due to the wallet's recent creation and the signi...
Starknet's native token, STRK, experienced a sharp decline of 10.32% within 60 minutes, falling to $0.10893 during a volatile trading session. Over the past 24 hours, STRK's price dropped 8.36%, trading between $0.10606 and $0.12486, with a trading v...
EigenCloud (EIGEN) token increased by 10% to $0.248 after rebounding from a support level near $0.22, supported by stronger trading volume and spot-market buyers. The token had bounced off its 200-day exponential moving average three days prior, indi...
Wormhole's native token, W, surged 61.39% in 24 hours to reach $0.02842, hitting a high of $0.02945 with $24 million in trading volume. The sharp rise reflects increased interest in altcoins, benefiting Wormhole as a key cross-chain infrastructure pr...
The DATA Network and its Trace registry have joined the Sui blockchain and Walrus data platform to provide a scalable, rights-cleared supply chain for AI training data. This integration enables AI labs to access real-world data with verified provenan...
